Elinzanetant Safe, Effective for Moderate-to-Severe Vasomotor Symptoms
TUESDAY, Sept. 30, 2025 -- Elinzanetant, a dual neurokinin-targeted therapy, is effective for treating menopause-associated moderate-to-severe vasomotor symptoms (VMS), according to a study published online Sept. 8 in JAMA Internal Medicine.
Nick Panay, M.B.B.S., from Imperial College London, and colleagues evaluated the 52-week efficacy and safety of elinzanetant for treating moderate-to-severe VMS associated with menopause. The analysis included 628 postmenopausal women aged 40 to 65 years who were seeking treatment for moderate-to-severe VMS and were randomly assigned to receive oral elinzanetant 120 mg once daily (313 women) or placebo (315 women).
The researchers found that at week 12, the mean change from baseline in daily moderate-to-severe VMS frequency was −5.4 for elinzanetant and −3.5 for placebo (least-squares mean difference for elinzanetant versus placebo, −1.6). Descriptive analyses showed numerical advantages for elinzanetant versus placebo for improving VMS frequency and severity over 50 weeks and sleep disturbances and menopause-related quality of life over 52 weeks. Elinzanetant was not associated with hepatotoxic effects, endometrial hyperplasia, or meaningful changes in bone density or bone turnover markers. Treatment-related adverse events were more common with elinzanetant than placebo (30.4 versus 14.6 percent), including somnolence, fatigue, and headache.
"Outcomes from this 52-week study were consistent with those observed in the 26-week OASIS-1 and OASIS-2 trials, contributing to the robustness of the findings and indicating the sustained benefit and safety of elinzanetant in a broad population with VMS over a prolonged duration of use," the authors write.
Several authors disclosed ties to relevant organizations.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Wrist Cooling May Help Manage Vasomotor Symptoms
WEDNESDAY, Sept. 24, 2025 -- Targeted wrist cooling may offer a safe approach for managing vasomotor symptoms, according to a study published online Sept. 20 in Endocrinology...
Age at Start of Estrogen Therapy May Affect Alzheimer Disease Risk
WEDNESDAY, Sept. 24, 2025 -- Estrogen therapy may reduce Alzheimer disease (AD) risk, with lower risk seen in association with early initiation, according to a study presented at...
Many Clinicians Not Comfortable With Hormone Therapy in Patients With History of Gynecologic Cancer
TUESDAY, Sept. 16, 2025 -- Many gynecologists and some gynecologic oncologists are uncomfortable prescribing hormone therapy to patients with a history of endometrial or...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.